Related Experiment Video

Updated: May 4, 2026

Isolation of Rat Portal Fibroblasts by In situ Liver Perfusion
07:39

Isolation of Rat Portal Fibroblasts by In situ Liver Perfusion

Published on: June 29, 2012

19.6K

Rifampin relieves pruritus in children with cholestatic liver disease

H A Cynamon1, J M Andres, R P Iafrate

  • 1Department of Pediatrics, University of Florida, Gainesville.

Gastroenterology
|April 1, 1990
PubMed

Insights

Rifampin effectively relieved severe itching in children with chronic cholestatic liver disease. This treatment showed sustained effectiveness and no complications, offering a new therapy option.

Area of Science:

  • Pediatric Hepatology
  • Gastroenterology
  • Clinical Pharmacology

Background:

  • Chronic cholestatic liver disease in children often causes severe, intractable pruritus.
  • Existing therapies, such as cholestyramine, are frequently ineffective for pediatric pruritus.

Purpose of the Study:

  • To evaluate the efficacy of rifampin in alleviating pruritus in pediatric patients with chronic cholestasis.
  • To assess the safety and sustained effectiveness of rifampin for pruritus management.

Main Methods:

  • A 6-week, double-blind, placebo-controlled crossover study was conducted.
  • Five pediatric patients with chronic cholestasis and severe pruritus participated.
  • Rifampin's effect on pruritus was compared to a placebo.

Main Results:

  • Rifampin demonstrated significant effectiveness in relieving pruritus in all five children.
  • The therapeutic benefit of rifampin was maintained during a subsequent 6-month treatment period.
  • No adverse complications were reported during rifampin administration.

Conclusions:

  • Rifampin is a highly effective treatment for severe pruritus associated with chronic cholestasis in children.
  • Careful patient selection and frequent monitoring are recommended for this therapy.
  • These findings, along with studies in adults, suggest rifampin as a promising therapeutic option.

More Related Videos

Cheek Injection Model for Simultaneous Measurement of Pain and Itch-related Behaviors04:59

Cheek Injection Model for Simultaneous Measurement of Pain and Itch-related Behaviors

Published on: September 27, 2019

12.6K
Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis05:56

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis

Published on: August 29, 2025

705

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
410
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
408
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
382
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
271
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
379
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
58